Pure Nano Genesis: Pioneering Universal Aqueous Nanostrategies from Pure Molecules to Revolutionise Diverse Applications

In this paper, we propose a novel universal approach for the construction of stable and aqueous nanoparticles, Pure Nano systems, comprising solely small conjugated molecules without any excipients. Our experiments confirm that the generation of surface charges plays an essential role during the spontaneous aggregation of conjugated molecules in the process of Pure Nano system fabrication, as it governs growth and confers physiochemical stability to particles at the nano scale. This approach overcomes solubility challenges in highly hydrophobic conjugated molecules by obviating excipients and enabling up to 100% drug loading capacity. Confirmation of this capability stems from the successful preparation of approximately 100 Pure Nano systems, incorporating different combinations of 27 conjugated molecules distinguished by their diverse dissociation types and degrees. The proposed preparation method is robust, simple, fast, and reliable, making it well-suited for large-scale manufacturing due to its array of unique features. This strategy affords a singular, molecular-focused approach, showcasing the intrinsic bioactivity of its constituent molecules while enabling aqueous dispersion for diverse applications. And in vivo experiments confirm the exceptional efficacy of various Pure Nano systems in reinstating dextran sodium sulfate induced acute ulcerative colitis to a healthy state, restoring myocardial ischemia/reperfusion injury to normal levels, and effectively treating cancer in mice with significantly improved median survival rates. This innovative nano drug delivery system represents a groundbreaking advancement with the potential to revolutionise translational nanomedicine. Positioned at the forefront of therapeutic possibilities, it is anticipated to substantially improve the efficacy and safety of nano therapies. This advancement heralds a new era, offering a highly targeted and efficient approach in the treatment of diverse medical conditions. ### Competing Interest Statement The authors have declared no competing interest.